HMGB2 and non-small cell lung carcinoma: No data were previously available about the role of HMGB1 or HMGB2 in the resistance to paclitaxel, olaparib or bevacizumab in EOC treatment, although HMGB1 had been reported as a possible prognosis biomarker of bevacizumab treatment in non-small-cell lung cancer [130] and bevacizumab and HMGB1 have been related to malignant mesothelioma [131].